Hydroxyzine

First-generation H1 receptor antagonist · also known as Atarax, Vistaril

First-generation H1 antihistamine; blocks histamine after release and has prominent central nervous system and cardiac safety boundaries.

How it relates to mast cells: Mast cell disease
Types of studies cited: Randomised controlled trial
Approved in the US for: histamine-mediated pruritus, including chronic urticaria
Randomised trials in: pediatric mastocytosis
Also covers: Diphenhydramine (Benadryl), Chlorpheniramine (Chlor-Trimeton), Clemastine (Tavist), Cyproheptadine

What this relationship means: Studied in patients with a different mast cell disease, usually systemic mastocytosis. Those disorders have diagnostic criteria and disease biology that differ from MCAS, so a result there does not establish an MCAS outcome. A 2025 practical-management review places this at step 1 of the sequence it describes — described as the initial treatment, with second-generation agents prioritised over first. That is what the review reports, not a recommendation from this site.

Mechanism of action

Hydroxyzine is a first-generation H1 receptor antagonist. It occupies the receptor that histamine would activate after mast-cell release, so its placement here is downstream of the mast cell rather than as a mast-cell stabiliser.

The current US label lists histamine-mediated pruritus, including chronic urticaria, among its uses. The mast-cell-disease trial compared hydroxyzine, ketotifen, and placebo in eight children with mastocytosis using a crossover design. Its age, size, and population make it a narrow evidence source rather than an MCAS trial.

Unlike less-sedating second-generation H1 antihistamines, hydroxyzine readily produces central nervous system effects. The current label’s drowsiness, CNS-depressant interaction, and cardiac-rhythm warnings are practical distinctions that remain visible alongside the study context rather than changing it.

Sources

H1-antihistamines for primary mast cell activation syndromes: a systematic review Review article 2016 PMID 26095756 · link checked 25 Aug 2026
Hydroxyzine pamoate current US prescribing information Drug label · link checked 21 Aug 2026
A double-blind, placebo-controlled, crossover trial of ketotifen versus hydroxyzine in the treatment of pediatric mastocytosis Peer-reviewed study 1989 PMID 2654254 · link checked 21 Aug 2026
Mast Cell Activation Syndrome and Mastocytosis: Initial Treatment Options and Long-Term Management Review article 2019 PMID 30961835 · link checked 21 Aug 2026

What this evidence cannot establish

No controlled study in MCAS supports this entry. The controlled evidence is in mast cell disease: a small, older crossover comparison in eight children with mastocytosis, which is not MCAS. A 2016 systematic review of H1-antihistamines in primary mast cell activation syndromes found only five crossover trials in total, enrolling 71 patients between them, and judged all five at moderate or high risk of bias — hydroxyzine is among the agents it names as historic and now less commonly used. This entry is recorded as studied in another mast-cell disease rather than downstream because the drug was studied in patients with a mast cell disease, which is what that field records; its mechanism still acts after histamine release. Hydroxyzine is a first-generation antihistamine with drowsiness and central nervous system depressant interactions on the current label; the label also contraindicates use with a prolonged QT interval and reports QT prolongation and torsade de pointes. Those safety boundaries are separate from the study context.

What this page does not say

No dosing, and no claim that this works. The entry describes a published mechanism, the cited study types, and what those studies cannot establish — nothing further. Why the site is built this way.

Recently verified. Verified 25 Aug 2026